Viridian Therapeutics (VRDN) Price & Analysis

Compare

1,457 Followers

VRDN Stock Chart & Stats

$32.11

-$0.90(-4.30%)

At close: Jan 08 4:00 PM EST

$32.11

-$0.90(-4.30%)

Day’s Range― - ―

52-Week Range$9.90 - $33.34

Previous CloseN/A

Volume201.32K

Average Volume (3M)814.59K

Market Cap

$3.06B

Enterprise Value$789.25M

Total Cash (Recent Filing)$490.90M

Total Debt (Recent Filing)$23.82M

Price to Earnings (P/E)―

Beta1.29

Next Earnings

Mar 05, 2026

EPS Estimate

-0.97

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding95,442,010

10 Day Avg. Volume1,087,693

30 Day Avg. Volume814,586

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)1.94

Price to Sales (P/S)4309.19

P/FCF Ratio-5.59

Enterprise Value/Market Cap0.26

Enterprise Value/Revenue11.15

Enterprise Value/Gross Profit11.15

Enterprise Value/Ebitda-2.64

Forecast

1Y Price Target

$41.03

Price Target Upside27.78% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering16

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessVeligrotug met all primary and secondary endpoints in Phase III clinical trials, showing rapid onset of clinical benefit and significant improvement in chronic TED.

Market PositioningVeligrotug offers a faster and more convenient treatment option with fewer infusions and shorter infusion times compared to the current standard of care, enhancing its market appeal.

Regulatory MilestonesThe FDA has accepted the biologics license application and granted priority review to veligrotug for the treatment of thyroid eye disease, indicating potential for a quicker commercial launch.

Bears Say

Viridian Therapeutics News

Viridian announces FDA acceptance of veligrotug biologics license application

Viridian Therapeutics (VRDN) announced that the FDA has accepted the biologics license application for veligrotug for the treatment...

4d ago

VRDN

3 Stocks Flashing Strong Buy Signals, Backed by Technical Analysis

As markets remain shaky, technical analysis helps investors find good stock opportunities. Using TipRanks’ Technical Analysis Screener, we...

9d ago

NGD

WVE

Argenx exit leaves more room for Viridian in TED, says Truist

Truist notes that Argenx (ARGX) announced the discontinuation of the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous in...

11d ago

ARGX

VRDN

Viridian Therapeutics rises 5.0%

Viridian Therapeutics (VRDN) is up 5.0%, or $1.61 to $33.92. Published first on TheFly – the ultimate source...

11d ago

VRDN

Viridian Therapeutics initiated with an Outperform at William Blair

William Blair initiated coverage of Viridian Therapeutics (VRDN) with an Outperform rating and $47 fair value estimate. The...

23d ago

VRDN

Viridian Therapeutics initiated with an Outperform at William Blair

William Blair initiated coverage of Viridian Therapeutics (VRDN) with an Outperform rating and $47 price target Published first...

23d ago

VRDN

Viridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on VRDN stock, giving a Buy rating...

3d ago

VRDN

Viridian: Priority Review for Veligrotug and Catalyst-Rich 2026 Outlook Drive Price Target Raise and Buy Rating

Needham analyst Serge Belanger maintained a Buy rating on Viridian Therapeutics today and set a price target of...

4d ago

VRDN

Viridian Therapeutics: Strong Market Position and Promising Catalysts Justify Buy Rating

Needham analyst Serge Belanger has maintained their bullish stance on VRDN stock, giving a Buy rating today. Serge...

11d ago

VRDN

Viridian Therapeutics Positioned for Growth in TED Market Amidst Competitive Setbacks

In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Viridian Therapeutics, with...

11d ago

VRDN

Viridian Therapeutics: Positioned for Growth with Promising Pipeline and Strong Financials

Laura Chico, an analyst from Wedbush, maintained the Buy rating on Viridian Therapeutics. The associated price target was...

16d ago

VRDN

Viridian Therapeutics initiated with a Buy at Truist

Truist initiated coverage of Viridian Therapeutics (VRDN) with a Buy rating and $41 price target The firm, which...

1M ago

VRDN

Promising Developments and Market Potential Drive Buy Rating for Viridian Therapeutics

TD Cowen analyst Joseph Thome has maintained their bullish stance on VRDN stock, giving a Buy rating on...

1M ago

VRDN

Viridian Therapeutics Advances Toward Profitability with Strategic Moves

Viridian Therapeutics, Inc. ( ($VRDN) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

VRDN

VRDN FAQ

What was Viridian Therapeutics’s price range in the past 12 months?

Viridian Therapeutics lowest stock price was $9.90 and its highest was $33.34 in the past 12 months.

What is Viridian Therapeutics’s market cap?

Viridian Therapeutics’s market cap is $3.06B.

When is Viridian Therapeutics’s upcoming earnings report date?

Viridian Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 69 days.

How were Viridian Therapeutics’s earnings last quarter?

Viridian Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$1.019 by $0.679.

Is Viridian Therapeutics overvalued?

According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Viridian Therapeutics pay dividends?

Viridian Therapeutics does not currently pay dividends.

What is Viridian Therapeutics’s EPS estimate?

Viridian Therapeutics’s EPS estimate is -0.97.

How many shares outstanding does Viridian Therapeutics have?

Viridian Therapeutics has 95,442,010 shares outstanding.

What happened to Viridian Therapeutics’s price movement after its last earnings report?

Viridian Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$1.019. Following the earnings report the stock price went up 8.293%.

Which hedge fund is a major shareholder of Viridian Therapeutics?

Currently, no hedge funds are holding shares in VRDN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Viridian Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-47.40%

Trailing 12-Months

Asset Growth

-0.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics (VRDN) Earnings & Revenues

Historic Earnings Reports

VRDN Stock 12 Month Forecast

Average Price Target

$41.03

▲(27.78% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","62":"$62","23.75":"$23.8","36.5":"$36.5","49.25":"$49.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$61.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.03,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.4047385,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,23.75,36.5,49.25,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.45,33.723076923076924,35.996153846153845,38.26923076923077,40.54230769230769,42.815384615384616,45.08846153846154,47.36153846153846,49.63461538461539,51.9076923076923,54.18076923076923,56.45384615384616,58.72692307692307,{"y":61,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.45,32.18692307692308,32.923846153846156,33.66076923076923,34.39769230769231,35.13461538461539,35.871538461538464,36.60846153846154,37.34538461538462,38.082307692307694,38.81923076923077,39.55615384615385,40.293076923076924,{"y":41.03,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.45,30.138826038461538,28.827652076923076,27.516478115384615,26.205304153846154,24.894130192307692,23.58295623076923,22.27178226923077,20.960608307692308,19.649434346153846,18.338260384615385,17.027086423076923,15.715912461538462,{"y":14.4047385,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.63,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.45,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >